Half Year 2026 PainChek Ltd Earnings Call Transcript
Key Points
- Painchek Ltd (ASX:PCK) has received FDA clearance for its adult pain assessment app, opening up the US market.
- The company has a significant reimbursement opportunity in the US, which is expected to be a game changer.
- Painchek Ltd (ASX:PCK) is embedded in close to 2,000 aged care facilities globally, with over 17 million pain assessments conducted.
- The company has a strong pipeline with a potential AUD1.9 million ARR, and a 30,000 bed pipeline opportunity in the US.
- Painchek Ltd (ASX:PCK) has a patent valid until 2038, providing a competitive advantage and protection against potential competitors.
- The last quarter saw a slower growth period with some small losses in the UK and Australia due to client consolidation and acquisitions.
- The transition from contracted licenses to implemented ones has been slow, although new contracts now have fixed implementation dates.
- The US market entry is still in its early stages, and the company is yet to fully capitalize on the reimbursement opportunities.
- Painchek Ltd (ASX:PCK) faces challenges in rapidly scaling its US operations despite having a team on the ground.
- The company has not yet secured specific reimbursement codes from CMS, which could impact the speed of revenue generation in the US.
Thanks for standing by and welcome to the PainChek Investor Webinar and Q&A, following the company's quarterly update announced this morning. Additionally, I'd refer everyone to yesterday's announcement regarding reimbursement in the US and this is something that we'll drill down on further during the webinar. (Event Instructions)
On behalf of PainChek today, we have the CEO and Managing Director, Phillip Davis. I'll hand it over to him now.
Thank you Matt, and thank you, everyone for attending today. I appreciate your time and the effort to be with us. Very excited to talk about our update this quarter and also to talk in more detail, as Matt mentioned about the pending -- about the existing, finding of the reimbursement opportunity for us in the United States, which we believe is a significant game changer for the business.
For those who are new to the story, PainChek's purpose is to give a voice to those people who can't reliably verbalize their pain, and that includes
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
